Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Recruiting · Phase 2 · NCT06849713
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL)
At a glance
- Research payments reported, 2025
- $808,945
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 80
About the trial
- Sponsor
- Massachusetts General Hospital (with BeOne Medicines)
- Tested
- Zanubrutinib (drug), Sonrotoclax (drug), Obinutuzumab (drug), Tacabrutideg (drug)
- Dates
- Started 2025-05-16; completion 2030-03-01
- Results posted
- Not yet
The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
From ClinicalTrials.gov, last updated 2026-08-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $808,945 in research payments for this study in 2025 (2 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $808,945
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.